Eli Lilly Acquired in-process research and development decreased by 19.4% to $528.80M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 179.5%, from $189.20M to $528.80M. Over 4 years (FY 2021 to FY 2025), Acquired in-process research and development shows an upward trend with a 35.0% CAGR.
High levels indicate an active inorganic growth strategy, while low levels suggest a focus on internal development.
This metric captures the costs associated with acquiring research and development projects from third parties that have...
Common in the pharmaceutical and biotech sectors where M&A is a primary strategy for pipeline replenishment.
is_lly_acquired_in_process_research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $25.00M | $174.00M | $376.60M | $165.60M | $440.40M | $62.40M | $240.10M | $105.00M | $97.10M | $2.98B | $622.60M | $110.50M | $154.30M | $2.83B | $189.20M | $1.57B | $153.80M | $655.70M | $528.80M |
| QoQ Change | — | +596.0% | +116.4% | -56.0% | +165.9% | -85.8% | +284.8% | -56.3% | -7.5% | >999% | -79.1% | -82.3% | +39.6% | >999% | -93.3% | +730.7% | -90.2% | +326.3% | -19.4% |
| YoY Change | — | — | — | — | >999% | -64.1% | -36.2% | -36.6% | -78.0% | >999% | +159.3% | +5.2% | +58.9% | -5.0% | -69.6% | >999% | -0.3% | -76.8% | +179.5% |
We use cookies for analytics. See our Privacy and Cookie Policy.